Abstracts Archive - Page 1068 of 2425 - ACR Meeting Abstracts

Abstract Number: 951 • 2018 ACR/ARHP Annual Meeting
IFN-Gamma Production in Lyme Arthritis Synovial Tissue Promotes Differentiation of Fibroblast-like Synoviocytes into Inflammatory Effector Cells
Robert Lochhead¹, David Ordonez-Del Valle¹, Sheila Arvikar², Allen C. Steere² and Klemen Strle³, ¹Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Harvard Medical School, BOSTON, MA, ²Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Department of Immunology and Inflammatory Diseases, Massachusetts General Hospital, Harvard Medical School, BOSTON, MA
Background/Purpose: Lyme arthritis (LA), a late-disease manifestation of Borrelia burgdorferi infection, usually responds to antibiotic therapy. However, some patients may develop a proliferative synovitis lasting…
Abstract Number: 952 • 2018 ACR/ARHP Annual Meeting
Effusion-Synovitis and Infrapatellar Fat Pad Edema Differentiate Accelerated Knee Osteoarthritis: Data from the Osteoarthritis Initiative
Julie Davis¹, Robert J. Ward², James MacKay³, Bing Lu⁴, Lori Lyn Price^5,6, Timothy E. McAlindon⁷, Charles B. Eaton⁸, Mary Barbe⁹, Grace H. Lo¹⁰, Matthew Harkey¹ and Jeffrey B. Driban¹¹, ¹Rheumatology, Tufts Medical Center, Boston, MA, ²Radiology, Tufts Medical Center, Boston, MA, ³Radiology, University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom, ⁴Brigham & Women's Hospital and Harvard Medical School, Boston, MA, ⁵Tufts Clinical and Translational Science Institute, Tufts University, Boston, MA, ⁶Biostatistics Research Center, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, ⁷Division of Rheumatology, Tufts Medical Center, Boston, MA, ⁸Family Medicine and Community Health( Epidemiology), Alpert Medical School of Brown University, Pawtucket, RI, ⁹Temple University School of Medicine, Philadelphia, PA, ¹⁰Michael E. DeBakey Veterans Affairs Medical Center / Baylor College of Medicine, Houston, TX, ¹¹Medicine, Division of Rheumatology, Tufts Medical Center, Boston, MA
Background/Purpose: Accelerated knee osteoarthritis (AKOA) is a unique endotype of knee osteoarthritis (KOA) that is characterized by a sudden onset of advance-stage disease and greater…
Abstract Number: 953 • 2018 ACR/ARHP Annual Meeting
Evaluating MRI-Detected Knee Inflammation Prior to Total Knee Replacement As a Predictive Biomarker of Clinically Important Pain Reduction Two Years Later
Manjinder Kaur¹, Lili Zhou², Erin L. Ashbeck², Ernest Vina³, Frank Roemer⁴, Ali Guermazi⁵, David J. Hunter⁶ and C. Kent Kwoh^1,2, ¹Division of Rheumatology, Department of Medicine, The University of Arizona, Tucson, AZ, ²University of Arizona Arthritis Center, Tucson, AZ, ³University of Arizona School of Medicine, University of Arizona Arthritis Center, Tucson, AZ, ⁴Department of Radiology, Boston University School of Medicine, Boston, MA, USA, Boston, MA, ⁵Boston University School of Medicine, Boston, MA, ⁶University of Sydney, Sydney, Australia
Background/Purpose: Some patients do not experience clinical improvement after total knee replacement (TKR). Presence of structural abnormalities on MRI before surgery may inform pain prognosis…
Abstract Number: 954 • 2018 ACR/ARHP Annual Meeting
A New Way to Think about Composite Magnetic Resonance Imaging Scores to Measure Osteoarthritis Severity and Progression
Lori Lyn Price^1,2, Jeffrey B. Driban³, Grace H. Lo⁴, Ming Zhang⁵, Michael P. LaValley⁶ and Timothy E. McAlindon⁷, ¹Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, ²Tufts Clinical and Translational Science Institute, Tufts University, Boston, MA, ³Medicine, Division of Rheumatology, Tufts Medical Center, Boston, MA, ⁴Michael E. DeBakey Veterans Affairs Medical Center / Baylor College of Medicine, Houston, TX, ⁵Tufts Medical Center, Boston, MA, ⁶Biostatistics, Boston University School of Public Health, Boston, MA, ⁷Division of Rheumatology, Tufts Medical Center, Boston, MA
Background/Purpose: For some rheumatologic diseases (e.g. lupus), separate scores evaluate cumulative damage and disease activity. No such strategy exists for osteoarthritis (OA). The prevailing approach…
Abstract Number: 955 • 2018 ACR/ARHP Annual Meeting
Lower Limb Muscle Strength and Protection Against Functional Decline and Structural Worsening in Knee Osteoarthritis
Alison H. Chang¹, Joan S. Chmiel², Orit Almagor¹, Karen W. Hayes¹, Ali Guermazi³, Prasad Pottumarthi⁴, Kirsten C. Moisio¹, Yunhui Zhang¹, Julie Szymaszek¹ and Leena Sharma⁵, ¹Northwestern University Feinberg School of Medicine, Chicago, IL, ²Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, ³Boston University School of Medicine, Boston, MA, ⁴NorthShore University HealthSystem, Evanston, IL, ⁵Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: Lower limb muscle weakness has been proposed as a factor contributing to functional decline and structural progression. Hip abductor strengthening, in addition to quadriceps…
Abstract Number: 956 • 2018 ACR/ARHP Annual Meeting
Bone Mineral Density Is a Causal Risk Factor for Knee and Hip Osteoarthritis: A Population-Based and Mendelian Randomization Study in the UK Biobank
Thomas Funck-Brentano¹, Maria Nethander², Sofia Moverare Skrtic¹, Pascal Richette³ and Claes Ohlsson¹, ¹Center for Bone and Arthritis Research, Department of Internal Medicine, Sahlgrensaka Academy, Gothenburg University, Gothenburg, Sweden, ²Bioinformatics Core Facility, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden, ³Lariboisière Hospital, Lariboisière, University of Paris 7, Paris, France
Background/Purpose: Osteoarthritis (OA) involves the whole joint, with alterations of cartilage, synovium and bone. Whether bone changes are a cause or consequence of the disease…
Abstract Number: 957 • 2018 ACR/ARHP Annual Meeting
Biomechanical Therapy for Osteoarthritis of the Knee: A Randomized Controlled Trial
Stephan Reichenbach^1,2, Sarah Heldner¹, Armando Lenz³, David T. Felson⁴ and Peter Jüni⁵, ¹Institute for Social and Preventive Medicine, Bern, Bern, Switzerland, ²Department of Rheumatology, Immunology and Allergology, Bern, Bern, Switzerland, ³CTU Bern, University of Bern, Bern, Switzerland, ⁴Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, ⁵Applied Health Research Centre (AHRC), Toronto, Toronto, ON, Canada
Background/Purpose: Biomechanics plays an important role in knee osteoarthritis (OA). A new biomechanical footwear system aims at altering knee loading patterns and retraining neuromuscular control…
Abstract Number: 958 • 2018 ACR/ARHP Annual Meeting
Tocilizumab and the Risk for Cardiovascular Disease Events Among Rheumatoid Arthritis Patients: A Direct Comparison in Real World Setting
Fenglong Xie¹, Huifeng Yun¹, Emily Levitan², Paul M. Muntner² and Jeffrey R. Curtis¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Multiple studies have observed unfavorable changes in lipid profile associated with tocilizumab (TCZ, anti-IL6 receptor antagonists) and some other rheumatoid arthritis (RA) therapies. The…
Abstract Number: 959 • 2018 ACR/ARHP Annual Meeting
The Prevalence of Methotrexate Associated Hepatotoxicity in a Multi-Hospital Health System
Elizabeth Pahomov¹, Yuliya Belopolsky¹, Arshad Ali¹ and Robert Woodrick², ¹Internal Medicine, NorthShore University HealthSystem, Evanston, IL, ²Rheumatology, NorthShore University HealthSystem, Evanston, IL
Background/Purpose: MTX has become the cornerstone in treatment of many rheumatologic disorders including rheumatoid arthritis and psoriasis. Although MTX can have a profound impact on…
Abstract Number: 960 • 2018 ACR/ARHP Annual Meeting
The Risk of Gastrointestinal Perforations Associated with Biologic Disease-Modifying Anti-Rheumatic Drugs Used in Rheumatoid Arthritis: A Nationwide Swedish Cohort Study
Andrei Barbulescu¹, Thomas Frisell¹, Johan Askling² and Bénédicte Delcoigne¹, ¹Clinical Epidemiology Unit, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, ²Unit of Clinical Epidemiology, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Gastrointestinal (GI) perforations occur more often than expected in patients with RA. Reports indicate that tocilizumab may be associated with an increased risk of…
Abstract Number: 961 • 2018 ACR/ARHP Annual Meeting
The Association of Biologic Drug-Levels with Infection Risk: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
Meghna Jani¹, William G Dixon¹, Mark Lunt¹, Diederik De Cock¹, John Isaacs², Ann Morgan³, Kath Watson¹, Anthony G. Wilson⁴, Anne Barton^5,6 and Kimme L. Hyrich^1,5, ¹Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ²Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, Great Britain, ⁴UCD School of Medicine and Medical Science, Conway Institute, University College Dublin, Dublin, Ireland, ⁵National Institute of Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁶Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, The University Of Manchester, Manchester, United Kingdom
Background/Purpose: High dose tumour necrosis factor inhibitor (TNFi) drugs are associated with an increased serious infection (SI) risk[1]. It is feasible that high biologic…
Abstract Number: 962 • 2018 ACR/ARHP Annual Meeting
Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 6 Years: An Updated Integrated Safety Analysis
Mark C. Genovese¹, Josef S. Smolen², Tsutomu Takeuchi³, Terence P. Rooney⁴, Christina L. Dickson⁴, Xiao-Yan Yang⁴, Chadi Saifan⁴, Anabela Cardoso⁴, Maher Issa⁴, Taeko Ishii⁵ and Kevin Winthrop⁶, ¹Stanford University Medical Center, Palo Alto, CA, ²Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, ³Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵Eli Lilly and Company, Kobe, Japan, ⁶Oregon Health and Science University, Portland, OR
Background/Purpose: Baricitinib (bari), an oral, selective inhibitor of Janus kinase (JAK) 1 and JAK 2, is approved for the treatment of moderately to severely active…
Abstract Number: 963 • 2018 ACR/ARHP Annual Meeting
Long-Term Safety of Tofacitinib up to 9.5 Years: A Comprehensive Integrated Analysis of the RA Clinical Development Program
Stanley Cohen¹, Yoshiya Tanaka², Xavier Mariette³, Jeffrey R. Curtis⁴, Eun Bong Lee⁵, Peter Nash⁶, Kevin Winthrop⁷, Christina Charles-Schoeman⁸, Lisy Wang⁹, Connie Chen¹⁰, Kenneth Kwok¹⁰, Pinaki Biswas¹⁰, Andrea Shapiro¹¹, Ann Madsen¹⁰ and Jürgen Wollenhaupt¹², ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²University of Occupational and Environmental Health, Kitakyushu, Japan, ³Paris-Sud University, Le Kremlin Bicêtre, France, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Seoul National University, Seoul, Korea, Republic of (South), ⁶University of Queensland, Brisbane, Australia, ⁷Oregon Health and Science University, Portland, OR, ⁸University of California, Los Angeles, CA, ⁹Pfizer Inc, Groton, CT, ¹⁰Pfizer Inc, New York, NY, ¹¹Pfizer Inc, Peapack, NJ, ¹²Schön-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Here, we report the largest integrated safety analysis of tofacitinib to date…
Abstract Number: 964 • 2018 ACR/ARHP Annual Meeting
Psoriatic Arthritis Impact of Disease (PsAID12) Was Provisionally Endorsed at Omeract 2018 As Core Instrument to Measure Psoriatic Arthritis-Specific Health-Related Quality of Life in Randomized Controlled Trials and Longitudinal Observational Studies
Richard Holland¹, Robin Christensen², Niti Goel³, Pil Hoejgaard⁴, William Tillett⁵, Laure Gossec⁶, Maarten de Wit⁷, Neil McHugh⁸, Philip J. Mease⁹, Beverly Shea¹⁰, Ying Ying Leung¹¹, Dafna D Gladman¹², Christine Lindsay¹³, Laura C. Coates¹⁴, Alexis Ogdie¹⁵, Vibeke Strand¹⁶, Lara Fallon¹⁷, Julie Birt¹⁸, Kristina Callis Duffin¹⁹, Oliver FitzGerald²⁰, Peter Tugwell²¹, Dorcas Beaton^22,23 and Ana-Maria Orbai²⁴, ¹Royal Prince Alfred Hospital Medical Centre, Sydney, Australia, ²Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg, Denmark, ³Kezar Life Sciences; Duke University School of Medicine, Durham, NC, ⁴Center for Rheumatology and Spine Diseases - Gentofte, Rigshospitalet, Hellerup, Denmark, ⁵Royal National Hospital for Rheumatic Diseases and University of Bath, Bath, United Kingdom, ⁶Sorbonne Universités, Paris, France, ⁷EULAR standing committee of PARE, Zurich, Switzerland, ⁸Rheumatology, Royal National Hospital, Bath, Great Britain, ⁹Swedish Medical Center and University of Washington, Seattle, WA, ¹⁰School of Epidemiology, Public Health, and Preventive Medicine, Faculty of Medicine, University of Ottawa, and Ottawa Hospital Research Institute, Clinical Epidemiology Program, Ottawa, ON, Canada, ¹¹Singapore General Hospital, Singapore, Singapore, ¹²University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ¹³Medical Affairs, Amgen Inc, Thousand Oaks, CA, ¹⁴University of Oxford, Oxford, United Kingdom, ¹⁵Medicine/Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA, ¹⁶Stanford University School of Medicine, Palo Alto, CA, ¹⁷Pfizer Canada, Montreal, QC, Canada, ¹⁸Eli Lilly and Company, Indianapolis, IN, ¹⁹Department of Dermatology, University of Utah, Salt Lake City, UT, ²⁰Department of Rheumatology, St. Vincent’s University Hospital, UCD School of Medicine and Medical Sciences and Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland, ²¹Center For Global Health, Institute of Population Hlth, Ottawa, ON, Canada, ²²University of Toronto, Musculoskeletal Health and Outcomes Research, St. Michael's Hospital and Institute for Work and Health, Toronto, ON, Canada, ²³University of Toronto, Department of Occupational Science and Occupational Therapy, Rehabilitation Sciences Institute, and the Institute for Health Policy Management and Evaluation, Toronto, ON, Canada, ²⁴Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: The GRAPPA-OMERACT PsA working group (WG) is using the OMERACT Filter 2.1 instrument selection algorithm1 to develop a Psoriatic Arthritis (PsA) core instrument set…
Abstract Number: 965 • 2018 ACR/ARHP Annual Meeting
Defining Cutoffs Corresponding to Low Levels of Disease Activity in Psoriatic Arthritis, Using the Patient-Reported Psoriatic Arthritis Impact of Disease Questionnaire (PsAID12). an Analysis of 436 Patients
Clémence Gorlier¹, Deborah Puyraimond-Zemmour¹, Ana-Maria Orbai², Laura C. Coates³, Uta Kiltz⁴, Ying Ying Leung⁵, Penelope Palominos⁶, Juan D. Cañete⁷, Rossana Scrivo⁸, Andra Rodica Balanescu⁹, Emmanuelle Dernis¹⁰, Sandra Tälli¹¹, Adeline Ruyssen-Witrand¹², Martin Soubrier¹³, Sibel Zehra Aydın¹⁴, Lihi Eder^15,16, Inna Gaydukova¹⁷, Ennio Lubrano¹⁸, Pascal Richette¹⁹, M. Elaine Husni²⁰, Maarten de Wit²¹, Josef S. Smolen²² and Laure Gossec²³, ¹Sorbonne Université, PARIS, France, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³University of Oxford, Oxford, United Kingdom, ⁴Rheumazentrum Ruhrgebiet, Herne, Germany, ⁵Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore, ⁶Rheumatology, Hospital de Clinicas de Porto Alegre, Santa Cecilia, Brazil, ⁷Rheumatology, Hospital Clinic and IDIBAPS, Barcelona, Spain, ⁸Department of Internal Medicine and Medical Specialties, Sapienza University, Rome, Italy, ⁹Department of Internal Medicine and Rheumatology “Sf. Maria” Hospital, Bucharest, Romania, ¹⁰Service de Rhumatologie, CH du Mans, Le Mans, France, ¹¹East-Tallinn Central Hospital, Department of Rheumatology, Tallinn, Estonia, ¹²Rheumatology, Purpan Hospital, Toulouse III University, Toulouse, France, ¹³Rheumatology, Department of Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, ¹⁴University of Ottawa, Ottawa, ON, Canada, ¹⁵Women's College Research Institute, University of Toronto, Women's College Hospital, Toronto, ON, Canada, ¹⁶Women's College Research Institute, Women's College Hospital, Toronto, ON, Canada, ¹⁷North-western state medical university n.a. II Mechnikov, St. Petersburg, Russian Federation, ¹⁸Department of Medicine and Health Sciences Vincenzo Tiberio, University of Molise, Campobasso, Italy, ¹⁹Lariboisière Hospital, Lariboisière, University of Paris 7, Paris, France, ²⁰Orthopedic and Rheumatologic Institute, Cleveland Clinic, Cleveland, OH, ²¹Dept. Medical Humanities, Amsterdam Public Health (APH), VU University Medical Centre, Amsterdam, Netherlands, ²²Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, ²³Rhumatologie, Médecine Sorbonne Université, Pitié-Salpétrière Hospital, Paris, France
Background/Purpose: The Psoriatic Arthritis (PsA) Impact of Disease questionnaire (PsAID12) score allows an assessment of patient-important symptoms and life impact in PsA. It is provisionally…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].